Janssen, part of Johnson & Johnson (J&J, US), has announced the opening of a special emerging-market business unit. This will unite the company's various access models under one group and bring what J&J terms as "innovative pricing" and "results-based financing models" to emerging markets. In addition to pricing and access, J&J will also seek to design, develop or tailor products towards emerging-markets needs and launch projects including the development of Sirturo (bedaquiline), long-acting rilpivirine, dapivirine microbicidal ring, developing reformulated versions of flubendazole and mebendazole, as well as participation in the UNITE project (a collaboration of research partners on HIV research).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
155.8 USD | +3.14% |
|
+4.04% | -0.82% |
04:15pm | Trending : Johnson & Johnson Beats 2Q Sales Guidance | DJ |
03:53pm | Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.82% | 363B | |
+57.09% | 848B | |
+31.64% | 627B | |
+14.93% | 318B | |
+12.19% | 299B | |
+15.36% | 243B | |
+16.77% | 225B | |
+15.51% | 179B | |
+3.59% | 167B | |
+2.43% | 125B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Launches Developing-World Business Unit